Literature DB >> 23300358

Ubiquitin pathway and ovarian cancer.

Z Rao1, Y Ding.   

Abstract

The ubiquitin-proteasome pathway is a common cellular process in eukaryotic tissue. Ubiquitin binds to proteins and tags them for destruction; this tagging directs proteins to the proteosome in the cell that degrades and recycles unneeded proteins. The ubiquitin-proteasome pathway plays an important role in the regulation of cellular proteins with respect to cell cycle control, transcription, apoptosis, cell adhesion, angiogenesis, and tumour growth. This review article discusses the various ways that the ubiquitin pathway is involved in ovarian cancer, such as modulating the ovarian-cancer-related gene BRCA1 and tumour suppressor p53, and interfering with the erk pathway, the cyclin-dependent cell cycle regulation process, and ERBB2 gene expression.

Entities:  

Keywords:  Ubiquitin; gene expression; ovarian cancer; protein degradation; therapy

Year:  2012        PMID: 23300358      PMCID: PMC3503665          DOI: 10.3747/co.19.1175

Source DB:  PubMed          Journal:  Curr Oncol        ISSN: 1198-0052            Impact factor:   3.677


  32 in total

1.  BRCA1 tumor suppression depends on BRCT phosphoprotein binding, but not its E3 ligase activity.

Authors:  Reena Shakya; Latarsha J Reid; Colleen R Reczek; Francesca Cole; Dieter Egli; Chyuan-Sheng Lin; Dirk G deRooij; Steffen Hirsch; Kandasamy Ravi; James B Hicks; Matthias Szabolcs; Maria Jasin; Richard Baer; Thomas Ludwig
Journal:  Science       Date:  2011-10-28       Impact factor: 47.728

2.  Proteasome-mediated degradation of BRCA1 protein in MCF-7 human breast cancer cells.

Authors:  Y H Choi
Journal:  Int J Oncol       Date:  2001-10       Impact factor: 5.650

3.  Developmental downregulation of Xenopus cyclin E is phosphorylation and nuclear import dependent and is mediated by ubiquitination.

Authors:  Yekaterina Brandt; Therese Mitchell; Yuehan Wu; Rebecca S Hartley
Journal:  Dev Biol       Date:  2011-04-22       Impact factor: 3.582

4.  Lactacystin enhances cisplatin sensitivity in resistant human ovarian cancer cell lines via inhibition of DNA repair and ERCC-1 expression.

Authors:  Q Q Li; M K Yunmbam; X Zhong; J J Yu; E G Mimnaugh; L Neckers; E Reed
Journal:  Cell Mol Biol (Noisy-le-grand)       Date:  2001       Impact factor: 1.770

5.  Regulators of the proteasome pathway, Uch37 and Rpn13, play distinct roles in mouse development.

Authors:  Amin Al-Shami; Kanchan G Jhaver; Peter Vogel; Carrie Wilkins; Juliane Humphries; John J Davis; Nianhua Xu; David G Potter; Brenda Gerhardt; Robert Mullinax; Cynthia R Shirley; Stephen J Anderson; Tamas Oravecz
Journal:  PLoS One       Date:  2010-10-27       Impact factor: 3.240

6.  BRCA2 is ubiquitinated in vivo and interacts with USP11, a deubiquitinating enzyme that exhibits prosurvival function in the cellular response to DNA damage.

Authors:  Alan R Schoenfeld; Sarah Apgar; Georgia Dolios; Rong Wang; Stuart A Aaronson
Journal:  Mol Cell Biol       Date:  2004-09       Impact factor: 4.272

7.  Cyclin G2 is degraded through the ubiquitin-proteasome pathway and mediates the antiproliferative effect of activin receptor-like kinase 7.

Authors:  Guoxiong Xu; Stefanie Bernaudo; Guodong Fu; Daniel Y Lee; Burton B Yang; Chun Peng
Journal:  Mol Biol Cell       Date:  2008-09-10       Impact factor: 4.138

Review 8.  Ubiquitin and breast cancer.

Authors:  Tomohiko Ohta; Mamoru Fukuda
Journal:  Oncogene       Date:  2004-03-15       Impact factor: 9.867

9.  Sef is a feedback-induced antagonist of Ras/MAPK-mediated FGF signalling.

Authors:  Maximilian Fürthauer; Wei Lin; Siew-Lan Ang; Bernard Thisse; Christine Thisse
Journal:  Nat Cell Biol       Date:  2002-02       Impact factor: 28.824

Review 10.  The BRCA1/2 pathway prevents hematologic cancers in addition to breast and ovarian cancers.

Authors:  Bernard Friedenson
Journal:  BMC Cancer       Date:  2007-08-06       Impact factor: 4.430

View more
  3 in total

1.  Ubiquitin-Proteasome Axis, Especially Ubiquitin-Specific Protease-17 (USP17) Gene Family, is a Potential Target for Epithelial-Mesenchymal Transition in High-Grade Serous Ovarian Cancer.

Authors:  Nuri Yildirim; Gizem Calibasi Kocal; Zerrin Isik; Bahadır Saatli; Ugur Saygili; Tugba Uysal; Cagnur Ulukus; Meral Koyuncuoglu; Hulya Ellidokuz; Yasemin Basbinar
Journal:  Reprod Sci       Date:  2018-09-09       Impact factor: 3.060

2.  Integrated bioinformatics analysis of validated and circulating miRNAs in ovarian cancer.

Authors:  Berkcan Dogan; Ece Gumusoglu; Ege Ulgen; Osman Ugur Sezerman; Tuba Gunel
Journal:  Genomics Inform       Date:  2022-06-30

3.  Detection of p53 and Bcl-2 expression in cutaneous hemangioma through the quantum dot technique.

Authors:  Tian Tang; Duan-Lian Zhang
Journal:  Oncol Lett       Date:  2017-03-13       Impact factor: 2.967

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.